drugset / Trial / NCT01392989

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

NCT01392989

Phase 2 Completed 44 enrolled Everett Meyer
NaSingle-groupOpen-labelTreatment

Summary

Allogeneic stem cell transplantation (transplant of blood cells from another individual) is a treatment option for patients with myelodysplasia or myeloproliferative Disorders. During the course of this study, it will be evaluated whether a particular type of blood cell, called a cytokine-induced killer (CIK) cell, may add benefit to allogeneic stem cell transplantation. CIK cells are present in small quantities in the bloodstream but their numbers can be expanded after a brief period of nurturing in a laboratory.

Timeline

Start
2011-03
Primary completion
2016-06-07
Completion
2017-03-19

Drugs

EvaluationDrugModalityDoseRoute
Subject CIK cells Cell therapy 1e+08 cells/kg
Background Cyclosporine Peptide 5 mg/kg Oral
Background Mycophenolate Mofetil Small molecule 15 mg/kg Oral
Background Thymoglobulin Protein / enzyme biologic 7.5 mg/kg Intravenous